Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments Sun Pharma recalls over 2,500 bottles of diabetes drug from US
The US arm of Sun Pharmaceutical Industries is recalling over 2,500 bottles of Metformin hydrochloride extended release tablets from Arizona on acco Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to announcement of financial results for the first quarter ending June 30, 2018, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Board Meeting Intimation for Notice Of Board Meeting For Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2018 And Dates Of Window Closure For Trading By Designated Persons.
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2018 ,inter alias, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2018. In view of the consideration of the above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from Friday,... Sun Pharma launches generic Glumetza tablets in US
Sun Pharmaceutical Industries today said one of its wholly-owned subsidiaries has launched generic metformin hydrochloride extended release tablets, Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to launch of Generic Glumetza Tablets in US, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Shareholding for the Period Ended June 30, 2018
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here
Sun Pharma's cancer injection from Halol plant gets USFDAnod
Sun Pharma's Halol plant had been under USFDA scanner since Sep 2014 and the quality cloud over it was lifted in June Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- ASHOK I BHUTADesignation :- Authorised Signatory Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- ASHOK I BHUTADesignation :- Authorised Signatory